Francisco Robert

4.8k total citations
107 papers, 3.2k citations indexed

About

Francisco Robert is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Francisco Robert has authored 107 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Oncology, 54 papers in Pulmonary and Respiratory Medicine and 33 papers in Molecular Biology. Recurrent topics in Francisco Robert's work include Lung Cancer Treatments and Mutations (51 papers), Lung Cancer Research Studies (32 papers) and Cancer therapeutics and mechanisms (16 papers). Francisco Robert is often cited by papers focused on Lung Cancer Treatments and Mutations (51 papers), Lung Cancer Research Studies (32 papers) and Cancer therapeutics and mechanisms (16 papers). Francisco Robert collaborates with scholars based in United States, Puerto Rico and Canada. Francisco Robert's co-authors include Sharon A. Spencer, Mansoor N. Saleh, Albert F. LoBuglio, Ruby F. Meredith, Frank V. Fossella, James A. Bonner, Harlan W. Waksal, Richard Wheeler, Delicia Carey and M.B. Khazaeli and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Francisco Robert

106 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Francisco Robert United States 28 1.8k 1.4k 1.1k 338 312 107 3.2k
Ann M. Mauer United States 23 1.3k 0.7× 1.1k 0.8× 908 0.8× 150 0.4× 315 1.0× 69 2.4k
Michael Millward Australia 25 1.7k 1.0× 1.1k 0.8× 1.1k 1.0× 117 0.3× 331 1.1× 43 2.9k
S. Kakolyris Greece 32 1.9k 1.1× 925 0.7× 1.0k 0.9× 286 0.8× 816 2.6× 90 3.0k
Y Ariyoshi Japan 31 3.2k 1.8× 2.8k 2.0× 2.0k 1.7× 697 2.1× 427 1.4× 127 5.5k
Frank Dunphy United States 25 2.4k 1.3× 2.1k 1.5× 735 0.7× 101 0.3× 476 1.5× 65 3.6k
Thierry Lesimple France 32 2.0k 1.1× 1.0k 0.7× 1.2k 1.0× 217 0.6× 401 1.3× 139 3.3k
Panos Fidias United States 25 1.7k 0.9× 1.8k 1.3× 925 0.8× 170 0.5× 276 0.9× 58 3.0k
Albiruni R. Abdul Razak Canada 29 2.0k 1.1× 1.1k 0.8× 1.1k 1.0× 172 0.5× 571 1.8× 96 3.5k
Paul Frankel United States 34 1.9k 1.1× 967 0.7× 1.8k 1.6× 134 0.4× 658 2.1× 214 4.1k
R. Wittes United States 25 1.5k 0.8× 692 0.5× 473 0.4× 262 0.8× 272 0.9× 51 2.7k

Countries citing papers authored by Francisco Robert

Since Specialization
Citations

This map shows the geographic impact of Francisco Robert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisco Robert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisco Robert more than expected).

Fields of papers citing papers by Francisco Robert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francisco Robert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisco Robert. The network helps show where Francisco Robert may publish in the future.

Co-authorship network of co-authors of Francisco Robert

This figure shows the co-authorship network connecting the top 25 collaborators of Francisco Robert. A scholar is included among the top collaborators of Francisco Robert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francisco Robert. Francisco Robert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Borghaei, Hossein, Mary W. Redman, Karen Kelly, et al.. (2020). SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). Clinical Lung Cancer. 22(3). 178–186. 8 indexed citations
2.
Bauer, Todd M., David R. Spigel, Neal Ready, et al.. (2016). ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC. Journal of Thoracic Oncology. 11(11). S252–S253. 11 indexed citations
3.
Ou, Sai‐Hong Ignatius, Ramaswamy Govindan, Keith D. Eaton, et al.. (2016). Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(1). 145–151. 40 indexed citations
4.
Jones, Benjamin, et al.. (2016). Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients. Cancer Chemotherapy and Pharmacology. 78(3). 509–515. 4 indexed citations
5.
Kim, Edward S., Marcus A. Neubauer, Allen Lee Cohn, et al.. (2013). Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. The Lancet Oncology. 14(13). 1326–1336. 50 indexed citations
6.
Blumenschein, George R., Tudor–Eliade Ciuleanu, Francisco Robert, et al.. (2012). Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study. Journal of Thoracic Oncology. 7(9). 1406–1416. 22 indexed citations
7.
Robert, Francisco. (2010). The potential benefits of low-molecular-weight heparins in cancer patients. Journal of Hematology & Oncology. 3(1). 3–3. 36 indexed citations
8.
Robert, Francisco, et al.. (2009). A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 65(2). 227–234. 12 indexed citations
9.
Leggas, Markos, Francisco Robert, Gretchen Cloud, et al.. (2008). Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. Cancer Chemotherapy and Pharmacology. 63(4). 731–743. 26 indexed citations
10.
Herbst, Roy S., Rafat Ansari, В. А. Горбунова, et al.. (2007). B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S335–S335. 2 indexed citations
11.
Cerfolio, Robert J., et al.. (2006). Women With Pathologic Stage I, II, and III Non-small Cell Lung Cancer Have Better Survival Than Men. CHEST Journal. 130(6). 1796–1802. 118 indexed citations
12.
Forero, Andres, Ruby F. Meredith, M.B. Khazaeli, et al.. (2005). Phase I Study of 90 Y-CC49 Monoclonal Antibody Therapy in Patients with Advanced Non-Small Cell Lung Cancer: Effect of Chelating Agents and Paclitaxel Co-Administration. Cancer Biotherapy and Radiopharmaceuticals. 20(5). 467–478. 19 indexed citations
13.
Belani, Chandra P., J. S. Lee, Mark A. Socinski, et al.. (2005). Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer. Annals of Oncology. 16(7). 1069–1075. 106 indexed citations
14.
Meredith, Ruby F., Sui Shen, Daniel J. Macey, et al.. (2003). Comparison of Biodistribution, Dosimetry, and Outcome from Clinical Trials of Radionuclide-CC49 Antibody Therapy. Cancer Biotherapy and Radiopharmaceuticals. 18(3). 393–404. 13 indexed citations
15.
Robert, Francisco, et al.. (2003). Chemotherapy Tolerance After Radioimmunotherapy with 90 Y-CC49 Monoclonal Antibody in Patients with Advanced Non-Small Cell Lung Cancer: Clinical Effects and Hematologic Toxicity. Cancer Biotherapy and Radiopharmaceuticals. 18(3). 317–325. 7 indexed citations
16.
Robert, Francisco, Sharon A. Spencer, Ruiwen Zhang, et al.. (2002). Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial. Lung Cancer. 37(2). 189–199. 10 indexed citations
17.
Buck, R.H., Francisco Robert, Ruby F. Meredith, et al.. (2000). Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer. 41. 634. 2 indexed citations
18.
Robert, Francisco, Seng-Jaw Soong, & Richard Wheeler. (1997). A Phase II Study of Topotecan in Patients with Recurrent Head and Neck Cancer. American Journal of Clinical Oncology. 20(3). 298–302. 28 indexed citations
19.
Moore, Malcolm J., Jean A. Maroun, Francisco Robert, et al.. (1993). Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer. Investigational New Drugs. 11(1). 61–65. 38 indexed citations
20.
Maroun, Jean A., et al.. (1988). Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study.. PubMed. 15(2 Suppl 2). 38–40. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ann M. Mauer Breakdown of academic impact, for papers by Michael Millward Breakdown of academic impact, for papers by S. Kakolyris Breakdown of academic impact, for papers by Y Ariyoshi Breakdown of academic impact, for papers by Frank Dunphy Breakdown of academic impact, for papers by Thierry Lesimple Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Albiruni R. Abdul Razak Breakdown of academic impact, for papers by Paul Frankel Breakdown of academic impact, for papers by R. Wittes
Rankless by CCL
2026